RF Acquisition Corp II
Definitive agreement 2025-10-02- CIK 2012807
- RFAI
- IPO 2024-05-17
- $44.9M trust
- 78 filings
- IPO Size
- $115M
- raised at the IPO
- Trust
- $44.9M
- as of 2026-09-30
- Current Status
- Proxy Vote
- from its latest filing
- IPO Year
- 2024
- year it listed
Filings, by quarter
78 filings over 12 quarters; violet bars carry a milestone
- 24 Q1: 1 filing
- 24 Q2: 22 filings
- 24 Q3: 3 filings
- 24 Q4: 5 filings
- 25 Q1: 1 filing
- 25 Q2: 4 filings
- 25 Q3: 4 filings
- 25 Q4: 10 filings
- 26 Q1: 6 filings
- 26 Q2: 8 filings
- 26 Q3: 11 filings
- 26 Q4: 3 filings
S-1 filed
IPO
Definitive agreement
- S-1 filed 24 Q1
- IPO 24 Q2
- Definitive agreement 25 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
RF Acquisition Corp II is a blank-check company seeking an initial business combination.
Investment Focus
Artificial Intelligence, Biopharmaceuticals
Geographic Focus
Asia
Key Information
As the filings state it
- IPO Date
- 2024-05-17
- Total Redemptions
- $80.9M
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- Merger Target
- Nanyang Biologics Pte. Ltd.
- SPAC Ticker
- RFAI
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
Led by Tse Meng Ng, a financier with prior SPAC leadership and banking and wealth-management experience, and Chee Soon Tham, a former Ernst & Young audit partner and outsourced-finance adviser. Directors Vincent Yang Hui and Ryan Lee Wen bring technology, e-commerce, medical-device, investment, and operating experience.